scholarly journals Long-term survival outcomes of laparoscopic extralevator abdominoperineal excision for low rectal cancer in a single center, high volume unit

2021 ◽  
Author(s):  
Zechuan Jin ◽  
Peilin Zhang ◽  
Xiangbing Deng ◽  
Ziqiang Wang
Keyword(s):  
Rectal Cancer ◽  
High Volume ◽  
Abdominoperineal Excision ◽  
Low Rectal Cancer ◽  
Survival Outcomes ◽  
Single Center ◽  
Term Survival ◽  
Long Term Survival ◽  
Volume Unit

Efficacy of Neoadjuvant Therapy in Improving Long-Term Survival of Patients with Resectable Rectal Cancer: A Meta-Analysis

2021 ◽  
Vol 21 ◽  
Author(s):  
Xinlong Li ◽  
Xiangyuan Li ◽  
Rongrong Fu ◽  
Derry Ng ◽  
Tong Yang ◽  
...  
Keyword(s):  
Rectal Cancer ◽  
Neoadjuvant Therapy ◽  
Meta Analysis ◽  
Low Rectal Cancer ◽  
Cochrane Library ◽  
Term Survival ◽  
Long Term Survival ◽  
Resectable Rectal Cancer ◽  
Long Term Prognosis

Background: The impact of neoadjuvant therapy on long-term prognosis of patients with resectable rectal cancer is currently unknown. Objective: This study aimed to explore the long-term prognosis of patients with resectable rectal cancer following treatment with neoadjuvant therapy. Methods: Four major databases (PubMed, Web of Science, Embase, Cochrane library) were searched to identify relevant articles published between January 2000 and July 2020. The main outcome indicators were the 5-year overall survival (OS) and disease-free survival (DFS). Results: The meta-analysis revealed that 5-year OS (HR: 0.88, 95% Cl: 0.83-0.93) and DFS (HR: 0.95, 95% Cl: 0.91-0.98) were higher in patients with resectable rectal cancer after receiving neoadjuvant therapy than those treated with upfront surgery. Subgroup analysis demonstrated that the long-term survival of patients in Asia and Europe could benefit from neoadjuvant therapy. The neoadjuvant short-course radiotherapy (SCRT) and neoadjuvant chemo-radiotherapy (CRT) improved the 5-year OS and DFS of patients with stage Ⅱ-Ⅲ rectal cancer and mid/low rectal cancer. Further research found that patients with stage Ⅱ only had an increase in OS, while patients with stage Ⅲ have improved 5-year OS and DFS. Conclusion: Neoadjuvant therapy improved the long-term survival of patients with mid/low rectal cancer in stage Ⅱ-Ⅲ (especially stage Ⅲ). Additionally, patients in Asia and Europe seemed to be more likely to benefit from neoadjuvant therapy. For the treatment, we recommend neoadjuvant SCRT and neoadjuvant CRT for resectable rectal cancer.

Comparison of long-term survival outcomes of operative versus nonoperative management of recurrent rectal cancer.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. e14132-e14132
Author(s):  
Aneel Bhangu ◽  
Mohammed Ali ◽  
David Cunningham ◽  
Gina Brown ◽  
Paris P Tekkis
Keyword(s):  
Rectal Cancer ◽  
Overall Survival ◽  
Recurrent Rectal Cancer ◽  
Survival Outcomes ◽  
R0 Resection ◽  
Term Survival ◽  
Long Term Survival ◽  
Primary Surgery ◽  
Significant Difference

e14132 Background: Complete surgical resection is considered the best treatment for recurrent rectal cancer (RRC). The aim of the study was to compare survival outcomes from operative and non-operative patients presenting with RRC. Methods: Patients with RRC whose management was discussed by a tertiary referral specialist multidisciplinary team between January 2007 and August 2011 were identified from a prospectively maintained database. The primary endpoint was 5-year overall survival estimated by Kaplan-Meier survival method. Results: Of 127 patients with RRC, 105 were isolated to the pelvis and 22 were associated with distant disease at presentation. From the time of primary surgery to first recurrence, 1, 3, 5 and 10-year local recurrence rates were 22%, 72%, 85% and 96% respectively. Of 70 patients (55%, 70/127) who underwent pelvic resection of recurrence, 64% underwent R0, 20% R1 and 16% R2 resections. Corresponding 5-year overall survival was R0: 60%, R1: 42% and R2: 0% (log-rank p=0.004). There was no significant difference in survival between R2 resection and those managed non-operatively (hazard ratio 0.738, 95% confidence interval 0.341-1.600, p=0.559). Five year disease-free survival was 53% with R0 resection and 30% with R1 resection. Conclusions: Most recurrences occur within 5 years of primary surgery, although some occur up to 10 years later. R0 resection is the treatment of choice that leads to long-term survival and is suitable as an early surrogate marker for long-term survival. There was no survival benefit of R2 resection over non-resected recurrences.

Nasal and paranasal sinus mucosal melanoma: Long-term survival outcomes and prognostic factors

2021 ◽  
Vol 42 (6) ◽  
pp. 103070
Author(s):  
Nicholas B. Abt ◽  
Lauren E. Miller ◽  
Tara E. Mokhtari ◽  
Derrick T. Lin ◽  
Jeremy D. Richmon ◽  
...  
Keyword(s):  
Prognostic Factors ◽  
Paranasal Sinus ◽  
Mucosal Melanoma ◽  
Survival Outcomes ◽  
Term Survival ◽  
Long Term Survival

scholarly journals Improved Long-Term Survival with Edaravone Therapy in Patients with Amyotrophic Lateral Sclerosis: A Retrospective Single-Center Study in Japan

2021 ◽  
Vol 14 (8) ◽  
pp. 705
Author(s):  
Hideki Houzen ◽  
Takahiro Kano ◽  
Kazuhiro Horiuchi ◽  
Masahiro Wakita ◽  
Azusa Nagai ◽  
...  
Keyword(s):  
Amyotrophic Lateral Sclerosis ◽  
Rank Test ◽  
Positive Pressure ◽  
Control Group ◽  
Single Center ◽  
Term Survival ◽  
Long Term Survival ◽  
Kaplan Meier ◽  
Lateral Sclerosis

Reports on the long-term survival effect of edaravone, which was approved for the treatment of amyotrophic lateral sclerosis (ALS) in 2015 in Japan, are rare. Herein, we report our retrospective analysis of 45 consecutive patients with ALS who initially visited our hospital between 2013 and 2018. Of these, 22 patients were treated with edaravone for an average duration of 26.6 (range, 2–64) months, whereas the remaining patients were not treated with edaravone and comprised the control group. There were no differences in baseline demographics between the two groups. The primary endpoint was tracheostomy positive-pressure ventilation (TPPV) or death, and the follow-up period ended in December 2020. The survival rate was significantly better in the edaravone group than in the control group based on the Kaplan–Meier analysis, which revealed that the median survival durations were 49 (9–88) and 25 (8–41) months in the edaravone and control groups, respectively (p = 0.001, log-rank test). There were no serious edaravone-associated adverse effects during the study period. Overall, the findings of this single-center retrospective study suggest that edaravone might prolong survival in patients with ALS.

scholarly journals Long-Term Survival in Pediatric Heart Transplantation: A 35-Year Single-Center Experience

2021 ◽  
Vol 40 (4) ◽  
pp. S34
Author(s):  
J.W. Wen ◽  
M.E. Richmond ◽  
S.P. Law ◽  
T.M. Lee ◽  
I.D. Lytrivi ◽  
...  
Keyword(s):  
Heart Transplantation ◽  
Single Center ◽  
Term Survival ◽  
Long Term Survival ◽  
Single Center Experience ◽  
Pediatric Heart Transplantation
Sign in / Sign up

Export Citation Format

Share Document